10V Stock Chart & Stats
€14.30
-€0.67(-5.16%)
At close: 4:00 PM EDT
€14.30
-€0.67(-5.16%)
Day’s Range― - ―
52-Week Range€4.36 - €14.34
Previous CloseN/A
Volume0.00
Average Volume (3M)214.00
Market Cap
€149.34M
Enterprise Value€498.91
Total Cash (Recent Filing)€155.10M
Total Debt (Recent Filing)€567.00K
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Oct 29, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.80
Shares Outstanding13,644,467
10 Day Avg. Volume546
30 Day Avg. Volume214
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-12.46
Price to Sales (P/S)0.00
P/FCF Ratio-0.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€30.73Price Target Upside114.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Improved EquityMinimal debt gives Immunic a relatively light fixed financial burden, while the return to positive and sizable TTM equity improves its capital structure versus 2025. This provides more flexibility to fund clinical development and manage obligations, although continuing losses could erode that cushion over time.
Lead Multiple Sclerosis Program AdvancingVidofludimus calcium remains the central strategic asset in Immunic’s pipeline, with management discussing progression toward confirmatory Phase 3 development in progressive multiple sclerosis. Advancing a lead program into later-stage trials could strengthen the company’s regulatory path and future commercial opportunity.
Experienced Financial And Strategic OversightAdding a director with extensive biopharmaceutical finance, capital-markets, corporate-development, and board experience strengthens oversight as Immunic approaches pivotal data and potential regulatory steps. This expertise may improve strategic financing and commercialization decisions during the next development phase.
Bears Say
No Revenue And Persistent Large LossesImmunic remains pre-commercial, so its operations do not yet generate recurring product revenue to offset research and corporate costs. Persistent, large operating losses leave future earnings dependent on successful development and eventual commercialization, limiting financial self-sufficiency over the next several quarters.
Heavy Cash Burn And Financing DependenceSubstantial recurring cash consumption means Immunic must continue funding clinical programs and operations without internally generated cash. Until revenue begins or spending is materially reduced, reliance on external financing remains a durable constraint on planning, financial flexibility, and the pace of development.
Potential Shareholder DilutionExpanding the equity incentive pool supports employee recruitment and retention but creates a continuing potential source of shareholder dilution. For a financing-dependent, pre-commercial company, additional equity issuance or stock compensation can reduce existing ownership percentages and raise the capital required to fund long-term development.
Immunic News
10V FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was €4.36 and its highest was €14.34 in the past 12 months.
What is Immunic’s market cap?
Immunic’s market cap is €149.34M.
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is Oct 29, 2026 which is in 49 days.
How were Immunic’s earnings last quarter?
Immunic released its earnings results on Aug 11, 2026. The company reported -€0.687 earnings per share for the quarter, beating the consensus estimate of -€1.001 by €0.314.
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate is -0.83.
How many shares outstanding does Immunic have?
Immunic has 13,644,467 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Immunic reported an EPS of -€0.687 in its last earnings report, beating expectations of -€1.001. Following the earnings report the stock price went down -1.071%.
Which hedge fund is a major shareholder of Immunic?
Currently, no hedge funds are holding shares in DE:10V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€30.73 (114.92% Upside)
€30.73 (114.92% Upside)
Blogger Sentiment
Bullish
DE:10V Sentiment 100%
Sector Average 60%
Sector Average 60%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
159.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunic
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
10V Stock 12 Month Forecast
Average Price Target
€30.73
▲(114.92% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―